Manufacturing Automation for Life Sciences: What It Is and Where It’s Used

Key takeaway: Manufacturing automation for life sciences means using robotics, continuous processing, and validated software to make drugs, vaccines, and medical products with less manual work. It cuts contamination risk, improves consistency, and helps factories meet strict FDA and EU quality rules — and it is becoming essential as drug shortages persist and sterile manufacturing faces sharper regulatory scrutiny.

What manufacturing automation means in life sciences

In pharmaceuticals, biotech, and medical devices, manufacturing automation goes well beyond robots on a production line. It covers robotic systems inside isolators and barrier setups that automate repetitive sterile tasks — vial filling, sealing, labeling — with minimal human interaction with the sterile product, which lowers contamination risk and reduces product losses, as BioPharma International and Contract Pharma report. It also covers manufacturing execution systems (MES), digital batch records, and real-time process monitoring — all operating under rules where every change must be documented and validated.

The keyword to remember is contamination. In sterile drug manufacturing, a single human touch can compromise a batch. Automated isolator filling lines can run continuously at a steady contamination risk level, while conventional lines need repeated cleaning, disinfection, and room-recovery downtime as operator presence raises the risk over time — so isolator lines produce higher quantities in less time, per Pharmaceutical Technology.

How PAT and continuous manufacturing changed the playbook

A major turning point was the FDA’s 2004 Process Analytical Technology (PAT) framework. PAT is “a system for designing, analyzing, and controlling manufacturing through timely measurements of critical quality and performance attributes,” with tools ranging from spectroscopy analyzers (NIR, Raman) to multivariate data analysis and process controls, according to Technology Networks. It gave manufacturers a regulatory path to measure quality in real time instead of testing it in at the end — and it sits within FDA’s cGMP rules for finished pharmaceuticals (21 CFR Part 211).

The next step was continuous manufacturing: instead of making drugs in discrete batches, product flows through one integrated process with online monitoring. ICH finalized the Q13 guideline on continuous manufacturing of drug substances and products in November 2022, with FDA adopting it in the US on March 1, 2023. FDA’s stated benefits: it eliminates manual handling and human error, increases quality assurance through online monitoring and control, reduces manufacturing time and capital costs through smaller equipment and less floor space, and responds more nimbly to drug shortages, per the agency’s announcement and BioPharma International. FDA now runs an Emerging Technology Program (since 2014) and the FRAME initiative prioritizing end-to-end continuous manufacturing, distributed manufacturing, point-of-care manufacturing, and AI in manufacturing.

The compliance backbone: validated software and electronic records

Automation in a regulated plant is inseparable from validation. Two standards dominate:

• 21 CFR Part 11 — the FDA rule under which electronic records and signatures are considered trustworthy, reliable, and equivalent to paper. It applies to drug makers, device manufacturers, biotech companies, biologics developers, and CROs, and requires controls including system validation, audit trails, and electronic signatures carrying the signer’s full name, date and time, and the meaning of the signature, per the regulation’s summary and SimplerQMS.
• ISPE GAMP 5, Second Edition (released July/August 2022) — the leading international guidance for validating computerized systems in regulated manufacturing, built around a risk-based lifecycle approach that prioritizes patient safety and product quality, per Jama Software and Cleanroom Technology.
• EU GMP Annex 1 (revised August 2022, effective August 25, 2023) — the sterile-products rule that made a documented Contamination Control Strategy mandatory and pushed the industry toward barrier technologies (RABS and isolators) plus tighter real-time environmental monitoring, per Dycem and HLC.

This is why automation vendors in life sciences sell compliance as much as they sell machinery: a system that cannot prove, in a validated electronic record, exactly what it did and when is useless in this industry.

Where automation is actually running today

The technology is already in production at some of the industry’s most visible sites. Siemens helped BioNTech convert its Marburg, Germany facility for mRNA COVID-19 vaccine production, cutting an estimated 12-plus-month timeline to about five months — using digitized paperless records, an automated weighing process replacing manual work, and digital twins that simulated facility capacity and fill volumes without sequential lab testing, per Fast Company. In 2020, Siemens and Atos partnered with GSK to pilot a digital twin of vaccine adjuvant particle manufacturing, combining computational fluid dynamics modeling with real plant data to predict product quality in real time, per BioPharma International.

The next frontier is cell therapy. On January 28, 2026, Cellares announced a $257 million Series D financing co-led by BlackRock and Eclipse (bringing total capital raised to $612 million) to build automated “Smart Factories” across South San Francisco, Bridgewater (NJ), Leiden, and Kashiwa City, Japan — targeting clinical manufacturing in the first half of 2026 and commercial scale in 2027. Cellares says it is the first company to receive FDA’s Advanced Manufacturing Technology designation (April 2025) for its closed, automated cell-therapy platform, per the company’s announcement and BioMed Nexus.

The underlying software market is growing with it: Grand View Research estimates the life sciences MES market at USD 3.3 billion in 2025, reaching USD 8.7 billion by 2033 (13.2% CAGR), driven by compliance, real-time tracking, and digital batch records, per their market report. (For how automation modernizes factories more broadly, including energy use, see our look at AI energy optimization in manufacturing; on choosing automation partners, see commercial automation services.)

Why it matters now: shortages and enforcement

Two pressures are making automation a necessity rather than a nice-to-have. First, drug shortages: ASHP recorded an all-time high of 323 active shortages in Q1 2024 — the most since it began tracking with the University of Utah in 2001 — and while the count fell to 214 by Q3 2025, roughly 75% of active shortages began in 2022 or earlier, with sterile injectables among the hardest to source, per Becker’s Hospital Review and Pharmacy Practice News. Continuous manufacturing is one of the few structural answers to this fragility, since automated lines respond faster than batch plants.

Second, enforcement. On September 22, 2026, FDA issued a warning letter to Fresenius Kabi’s Melrose Park sterile injectables facility — a site with capacity above 160 million vials a year — citing media-fill failures on multiple aseptic filling lines in 2024 and 2025, at least nine incidents of extrinsic biological contamination including hair dating back to May 2022, and an endotoxin failure that led to recalls of famotidine injection batches, per PharmaTutor and BioPharma International. Cases like this are exactly why regulators and buyers now treat strong aseptic automation and contamination control as baseline expectations, not upgrades.

Analysis: what adopting it actually takes

Analysis: The following is practical guidance synthesized from the sources above, not a vendor recommendation.

Automation in life sciences is not plug-and-play. Every computerized system must be validated under a risk-based approach (GAMP 5), every record must survive Part 11 scrutiny, and sterile sites now need a documented Contamination Control Strategy. The practical adoption path most sites follow: first automate the highest-risk manual touchpoints (aseptic fill-finish, weighing), then replace paper batch records with validated electronic ones, then layer in PAT instruments and MES integration for real-time control. The common failure mode is buying the robot before fixing the process — automation faithfully amplifies whatever process you give it, and in a GMP environment the auditor will notice. Finally, expect validation to take as long as installation: the paperwork is part of the product.

Frequently asked questions

What is manufacturing automation for life sciences?

It is the use of robotics, continuous processing, and validated software to manufacture drugs, vaccines, and medical products with minimal manual intervention. In practice it covers robotic fill-finish lines inside isolators, manufacturing execution systems, digital batch records, and real-time quality monitoring — all operating under FDA cGMP and EU GMP rules that require every step to be documented and validated.

What are PAT and continuous manufacturing?

Process Analytical Technology (PAT), defined in FDA’s 2004 framework, is a system for controlling manufacturing through timely measurements of critical quality attributes, using tools like spectroscopy analyzers and data analysis. Continuous manufacturing makes drugs in one integrated flowing process instead of discrete batches, with online monitoring — ICH finalized the Q13 guideline on it in November 2022. Together they let manufacturers measure quality during production rather than only testing it at the end.

Why is compliance such a big part of life sciences automation?

Because regulators hold drug makers to proof, not just performance. Under 21 CFR Part 11, electronic records and signatures must be as trustworthy as paper, with audit trails and validation. ISPE’s GAMP 5 (second edition, 2022) guides validation of computerized systems, and the revised EU GMP Annex 1 (effective August 2023) mandates a documented Contamination Control Strategy for sterile manufacturing. An automated system that cannot prove what it did, when, is useless in this industry.

Which companies are using automation in life sciences manufacturing?

BioNTech’s Marburg facility was converted to automated mRNA vaccine production with Siemens’ help, cutting an estimated 12-plus-month timeline to about five months with paperless records and digital twins. GSK piloted a digital twin for vaccine adjuvant manufacturing with Siemens and Atos in 2020. Cellares is building automated cell-therapy “Smart Factories” on four continents after a $257 million Series D in January 2026, and says it holds FDA’s first Advanced Manufacturing Technology designation for its automated cell-therapy platform.

Sources

• Technology Networks — “What Is Process Analytical Technology (PAT)?”
• PharmTech — “Quality Systems for the 21st Century: Process Analytical Technology”
• FDA — CDER’s FRAME initiative
• FDA — Draft guidance ICH Q13 announcement
• BioPharma International — “Continuous Manufacturing Gains Major Push from FDA”
• Wikipedia — “Title 21 CFR Part 11”
• SimplerQMS — “FDA 21 CFR Part 11 Questions and Answers”
• Jama Software — “What is GAMP 5”
• Cleanroom Technology — “ISPE GAMP5 second edition: What’s new?”
• Dycem — “What are the regulatory requirements for a contamination control strategy?”
• HLC — “Can sterile drug manufacturers implement EU GMP Annex 1 requirements?”
• BioPharma International — “Advances in Digitalization and Automation of Aseptic Processing”
• Contract Pharma — “Why Robotic Sterile Fill-Finish Is Key”
• Pharmaceutical Technology — “The advantages of isolator lines for large-scale pharma manufacturing”
• Fast Company — Siemens/BioNTech digitalization
• BioPharma International — “Opportunities for Digital Twins”
• Cellares — “$257 Million Series D” announcement
• BioMed Nexus — “Cellares Raises $257M to Scale Automated ‘Smart Factories'”
• Grand View Research — MES in life sciences market report
• Becker’s Hospital Review — ASHP drug shortage data
• Pharmacy Practice News — Drug Shortages ASHP Report 2025
• PharmaTutor — Fresenius Kabi warning letter
• BioPharma International — Fresenius Kabi warning letter